Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors
about
The DNA-damage response in human biology and diseaseDNA damage and repair in atherosclerosis: current insights and future perspectivesStructure and function of the ARH family of ADP-ribosyl-acceptor hydrolasesSIRT3 in Cardiac Physiology and DiseasePathophysiological Role of Peroxynitrite Induced DNA Damage in Human Diseases: A Special Focus on Poly(ADP-ribose) Polymerase (PARP)New approaches of PARP-1 inhibitors in human lung cancer cells and cancer stem-like cells by some selected anthraquinone-derived small moleculesADP-ribosyl-acceptor hydrolase 3 regulates poly (ADP-ribose) degradation and cell death during oxidative stressThe orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1PARP inhibition: PARP1 and beyondInvestigating Prevalence and Pattern of Long-term Cardiovascular Disorders in Sulphur Mustard-exposed Victims and Determining Proper Biomarkers for Early Defining, Monitoring and Analysis of Patients' Feedback on Therapy.Essential versus accessory aspects of cell death: recommendations of the NCCD 2015.PARP-inhibitor treatment prevents hypertension induced cardiac remodeling by favorable modulation of heat shock proteins, Akt-1/GSK-3β and several PKC isoforms.Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress.Poly(ADP-ribose) polymerase inhibitors in triple-negative breast cancer.Trypanosoma cruzi induces the reactive oxygen species-PARP-1-RelA pathway for up-regulation of cytokine expression in cardiomyocytes.Vincristine attenuates N-methyl-N'-nitro-N-nitrosoguanidine-induced poly-(ADP) ribose polymerase activity in cardiomyocytes.A deficiency of apoptosis inducing factor (AIF) in Harlequin mouse heart mitochondria paradoxically reduces ROS generation during ischemia-reperfusionNew facets in the regulation of gene expression by ADP-ribosylation and poly(ADP-ribose) polymerases.Antiapoptotic effects of Phe140Asn, a novel human granulocyte colony-stimulating factor mutant in H9c2 rat cardiomyocytesTargeting poly(ADP-ribose) polymerase activity for cancer therapy.Regulatory role of mitochondria in oxidative stress and atherosclerosis.Poly(ADP-ribose) polymerase-1 (PARP-1) gene deficiency alleviates diabetic kidney disease.The biochemical pathways of central nervous system neural degeneration in niacin deficiency.Reduced estradiol-induced vasodilation and poly-(ADP-ribose) polymerase (PARP) activity in the aortas of rats with experimental polycystic ovary syndrome (PCOS).Inhibition of poly (ADP-ribose) polymerase and inducible nitric oxide synthase protects against ischemic myocardial damage by reduction of apoptosis.Resveratrol attenuates azidothymidine-induced cardiotoxicity by decreasing mitochondrial reactive oxygen species generation in human cardiomyocytesCardiac function and disease: emerging role of small ubiquitin-related modifier.Complement dependency of cardiomyocyte release of mediators during sepsisFermented wheat germ extract (avemar) in the treatment of cardiac remodeling and metabolic symptoms in rats.PARP-1 deficiency blocks IL-5 expression through calpain-dependent degradation of STAT-6 in a murine asthma model.Opposing roles of PARP-1 in MMP-9 and TIMP-2 expression and mast cell degranulation in dyslipidemic dilated cardiomyopathy.Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibiting PARP.Low shear stress induced HMGB1 translocation and release via PECAM-1/PARP-1 pathway to induce inflammation responseCaspase-Dependent and Caspase-Independent Pathways Are Involved in Cadmium-Induced Apoptosis in Primary Rat Proximal Tubular Cell Culture.Doxorubicin-induced necrosis is mediated by poly-(ADP-ribose) polymerase 1 (PARP1) but is independent of p53.Drug-induced mitochondrial dysfunction and cardiotoxicity.Role of the peroxynitrite-poly(ADP-ribose) polymerase pathway in human disease.Therapeutic applications of PARP inhibitors: anticancer therapy and beyondMetabolic dysfunction in diabetic cardiomyopathy.Inflammation and endothelial dysfunction during aging: role of NF-kappaB
P2860
Q24606586-87693177-B71A-4893-8706-EE8F7A0F1963Q27001756-D30AF5EB-A8DF-4005-8C54-95C8494F1509Q27004584-FE2CCBFF-EB55-4481-9430-DD9310517F67Q28076837-84EFC725-3120-490E-A452-648431D0E341Q28080057-2F29EF1D-D3CD-41E2-9571-DE613FA11722Q28486776-D865AC85-774C-4411-96EC-21DA7400CA99Q28504824-45EABED1-BD04-45ED-BBA5-B7DA91DF1FE6Q28581148-082AC088-921C-4E5F-A0A8-E8D09D4AF3BFQ29619617-D58B56CD-D2BC-41CE-8A4A-0ABCA2FFD096Q30245541-279CB99D-33ED-48CA-99E9-F20F883A499FQ30408769-0F70364E-D4E6-4F60-A632-5B09D251F41FQ30434858-8FCFDF61-0386-47A5-8C5A-AC548AD599B6Q33510142-B7036330-AAD6-42BD-9585-A1B592CF9850Q33669053-3042621B-47D6-4A3E-AA35-8402C311E2C8Q33799832-87CDA459-FCAB-4B55-82A1-492C825B4867Q33832010-AC98FC6F-606F-4ADC-A21D-498B0E59FB5DQ33930671-96F68312-A59F-4BBE-B39A-CCA879D7DEB2Q34042969-56A7EF1C-DE37-4F3B-9481-D51487D6488EQ34049210-58FBB6C4-1AB6-42AE-B21B-4E13FC2F6545Q34204660-F05F61FD-2207-4EE2-842F-96D4FA647DD7Q34390683-A2790D91-7D14-40EB-94C0-3BF2B7F22F56Q34441033-446E6280-4556-4F2E-A88D-27FF94C0E131Q34443624-9F7A7DBB-D0CB-4713-96D0-64AECF300A5EQ34650147-FA4932E7-1C4C-44FE-A721-80A066BE0595Q34731311-D61EB27C-1DE3-4C85-A92A-9E45585E3122Q34787965-14C9B768-8294-4110-8FB6-9ACD1D3A25CBQ35032636-0DF7A230-30E6-45FD-8DAB-D8E79DDCC886Q35043866-B072FFED-29C1-445E-804B-D9DE0FC16072Q35103679-D48202C3-B47F-46E8-8DCA-E918D12CCFD3Q35148141-D6643EF6-492F-4134-A3DF-F2FBAF2C3763Q35176333-BC48A682-EDC6-4E8C-867C-BFDDD2BCB9D7Q35287136-2903DFB4-D1ED-46E5-B87B-F9E6DC9B5E6FQ35582672-B3A229E3-B827-41B3-92E1-F217E90CBE38Q36197657-D812D527-D02D-4EC5-8675-6B47984D0174Q36237705-6DCC7F75-D183-46F6-9346-22580FF81CA5Q36339445-52555694-40BF-4F58-8F30-D521C66BD5E6Q36734840-D7E38344-10C5-42F4-85B9-FCD73F1259B6Q36853236-0EE99CB5-989B-4C78-ABD5-91BB3598B071Q36930481-177DBB92-C38B-46E6-B10C-6D2F9C0773AFQ36956379-28023C59-AE83-4B27-B450-D26D6FBE7B3F
P2860
Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@ast
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@en
type
label
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@ast
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@en
prefLabel
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@ast
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@en
P2860
P1476
Role of poly(ADP-ribose) polym ...... c potential of PARP inhibitors
@en
P2093
Csaba Szabó
P2860
P304
P356
10.1111/J.1527-3466.2007.00018.X
P50
P577
2007-01-01T00:00:00Z